Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.70 |
| ▸ | CD69 | Q07108 | 10/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16814200 | 1.00 | BTK (0.70) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL16793902 | 1.00 | BTK (0.70) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL29676546 | 1.00 | BTK (0.70) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL16794481 | 1.00 | BTK (0.70) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL29676659 | 0.94 | BTK (0.69) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL29676650 | 0.94 | BTK (0.69) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL16814181 | 0.94 | BTK (0.69) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL16794239 | 0.94 | BTK (0.69) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL16814180 | 0.94 | BTK (0.69) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL16794130 | 0.93 | BTK (0.70) | BTKCD69CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885CD69 3940/4885CYP2C9 1939/4885 |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885CD69 3940/4885CYP2C9 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.